
Amgen Stock Recovers After Addressing Weight-Loss Drug Concerns
Amgen's stock rebounded after concerns about its weight-loss drug MariTide causing bone mineral density loss were deemed "overdone" by analysts. Despite a 7% stock drop due to initial fears, experts argue that significant weight loss often correlates with reduced bone density. Amgen maintains confidence in MariTide, with Phase 2 trial results expected later this year. Analysts note that while rival drugs from Eli Lilly and Viking Therapeutics may offer bone health benefits, the impact of MariTide remains uncertain pending further data.


